HANALL BIOPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35,250 KRW | -1.12% |
|
+2.32% | -20.43% |
| Sales 2024 * | 143B 106M 8.81B | Sales 2025 * | 164B 121M 10.1B | Capitalization | 1,787B 1.32B 110B |
|---|---|---|---|---|---|
| Net income 2024 * | 7B 5.17M 431M | Net income 2025 * | 12B 8.86M 738M | EV / Sales 2024 * | 12.3 x |
| Net cash position 2024 * | 28B 20.66M 1.72B | Net cash position 2025 * | 61.57B 45.44M 3.79B | EV / Sales 2025 * | 10.5 x |
| P/E ratio 2024 * |
255
x | P/E ratio 2025 * |
147
x | Employees | 306 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.12% | ||
| 1 week | +2.32% | ||
| Current month | -2.35% | ||
| 1 month | -1.54% | ||
| 3 months | +17.30% | ||
| 6 months | +10.50% | ||
| Current year | -20.43% |
1 week
34 500.00
36 500.00
1 month
31 450.0036 500.00
Current year
28 550.0044 800.00
1 year
18 400.0046 750.00
3 years
12 450.0046 750.00
5 years
12 450.0046 750.00
10 years
3 555.0046 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Su-jin Park
CEO | Chief Executive Officer | - | 29/23/29 |
Seung-Kook Park
CEO | Chief Executive Officer | 61 | - |
Seung-Won Jeong
BRD | Director/Board Member | 53 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Chun Yoon
BRD | Director/Board Member | 64 | 30/15/30 |
Seung-Kook Park
CEO | Chief Executive Officer | 61 | - |
Sung-Yeon Im
BRD | Director/Board Member | 55 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 7 M€ | +3.48% | - | |
| 0.00% | 117 M€ | +2.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 35,250 | -1.12% | 216,588 |
| 02/24/02 | 35,650 | -1.25% | 207,307 |
| 30/24/30 | 36,100 | +2.12% | 384,496 |
| 29/24/29 | 35,350 | +1.73% | 172,632 |
| 26/24/26 | 34,750 | +0.87% | 280,171 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
Hanall Biopharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of synthetic pharmaceuticals and biopharmaceuticals. The Company mainly manufactures and sells pharmaceutical products including antidiabetic drugs, skin drugs, muscle relaxants, hepatitis drugs, digestion drugs, anti-cardiovascular drugs, neurologic drugs, interferons, antiviral drugs, antibiotics, antihistamine, anti-inflammatory drugs, and others. The Company also engages in the leasing of real estates. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
35,250
KRW
Average target price
48,000
KRW
Spread / Average Target
+36.17%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.43% | 1.32B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- A009420 Stock
